Igy_presentation Jan 2010 NML WPG
-
Upload
brainboxonline -
Category
Documents
-
view
218 -
download
0
Transcript of Igy_presentation Jan 2010 NML WPG
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
1/52
BEYOND ANTIBIOTICS -TREATING VIRUSES & BACTERIA PATHOGENS WITH
SPECIFIC ANTIBIODIES - AND ELIMINATING THE SIDE
EFFECTS IN THE PROCESS.
JANUARY 26TH - NATIONAL MICROBIOLOGY LABORATORY
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
2/52
IGY Immune Technologies & Life Sciences Inc.
SAFE HARBOUR STATEMENTS
The information in this presentation is being made available to you and a limited number of other prospective investors on a confidential
basis, solely for the purpose of your consideration of an investment in securities under a securities purchase agreement, and such
information may not be used for any other purpose.
The information contained herein has been obtained from IGY Immune Technologies and Life Sciences Inc. (the Company) and from
sources believed by the Company to be reliable. The Company makes no representations or warranties, express or implied, as to the
accuracy or completeness of this information. The Company expressly disclaims any and all liability from any untrue statements or
omissions, which may be contained in this presentation or any other written or oral communication transmitted or made available to a
prospective investor. Only those particular representations made in a securities purchase agreement shall have any legal effect.
Certain statements in this presentation, such as those concerning the Companys business strategy, products, revenues and capital
requirements, and other statements regarding matters that are not historical facts, and the Companys financial projections included herein,
are forward-looking statements (as defined in the securities act of 1933). Because such forward-looking statements include
risk and uncertainties, actual results may differ materially from those expressed in or implied by such forward-looking statements.
During the course of your evaluation, all inquiries and other communications are to be made only to employees or representatives of the
Company. Accordingly, you agree not to directly or indirectly discuss with, or offer to, any third party a participation in a possible transaction
or any other form of joint investment or acquisitionby you and such third party without The Companys prior written consent.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
3/52
IGY Immune Technologies & Life Sciences Inc.
PRESENTATION OVERVIEW
Overview
What We Do
Our Mission
The Trillion Dollar Health and Wellness Market
Building Immune Systems and Treating Specific World Health Problems
The Technology
Market Segments:
Medicines
Functional Foods
Agribusiness & Packaged Consumer Meat Producers
Cosmeceuticals
Corporate Structure
Strategic Timeline
Leverage Through Partnerships
Financial Forecasts
Financing Objectives
Management Team, Consultants, Advisory Board, Board Of Directors
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
4/52
IGY Immune Technologies & Life Sciences Inc.
WHAT WE DO
IGY Immune Technologies and Life Sciences specializes in the extraction of
polyclonal immunoglobulin antibodies, a type of antibodies that are derived fromchicken eggs for use as a nutraceutical for human consumption.
Immunoglobulins are powerful antibodies produced in healthy humans and other
animals to fight infections and prevent disease. Egg yolks contain immunoglobulin
IgY, the functional equivalent of immunoglobulin IgG which makes up 75% of the
immunoglobulin found in healthy human plasma.
Our proprietary technology and processes makes it possibleto create health products to strengthen and supplement yournatural immune system against certain types of bacteriaviruses and other autoimmune ailments.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
5/52
IGY Immune Technologies & Life Sciences Inc.
OUR MISSION
IgY Immune Technologies and Life Sciences Inc. is in the business of designing specific antibodies through natural
sources and purifying them through its proprietary extraction methods. By introducing specific antibodies to theanimal kingdom, we have the ability to prevent disease, save lives and reduce our dependence on antibiotics.
By improving the bodys natural immune system, like never before, we can improve the lives of millions suffering
from viral, bacterial, and autoimmune diseases.
By preventing the spread of disease, we can save hundreds of billions in valuable tax resources; allowing
governments to redirect their resources into other areas of science, to lower the costs of healthcare systems
around the world and ultimately, bring IgY medicine to the developing world.
By arming veterinary science with improved methods to farm our agriculture and aquaculture industries, we will
create a stronger food network and at the same time, a safer drinking water system by reducing its over use of
antibiotic drugs.
By extending these same specific antibodies to our family pets, they can live longer, healthier lives for everyone
to enjoy.
By putting into effect the knowledge of immunologists and microbiologists around the world, our scope of
science to be discovered is incredible.
By achieving all of this, our stakeholders will be pioneers in medical science and earn a valuable share in our
financial successes.
The Cure is in the Prevention. IgY for Life.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
6/52
IGY Immune Technologies & Life Sciences Inc.
THE TRILLION DOLLAR HEALTH & WELLNESS MARKET
THE MARKET OPPORTUNITY
Public health awareness continues to shift towards disease prevention
Boosting immune systems will become an increasingly important focus
Dietary supplements and vitamins, already used extensively, don't contain the
antibodies needed to fight off or prevent disease
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
7/52
IGY Immune Technologies & Life Sciences Inc.
THE TRILLION DOLLAR HEALTH & WELLNESS MARKET
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
8/52
IGY Immune Technologies & Life Sciences Inc.
Alexander FlemingDiscovered Penicillin, 1928
80 YEARS OF ANTIBIOTICS
BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS
In his 1945 Nobel Prize address,
Alexander Fleming warned that it
was easy to produce microbes
resistant to his discovery, penicillin.
Simply expose them to concentrations
of the drug was insufficient to killthem.
John Hopkins Magazine, John Hopkins University
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
9/52
IGY Immune Technologies & Life Sciences Inc.
BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS
Viral Bacteria
Autoimmune
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
10/52
IGY Immune Technologies & Life Sciences Inc.
BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
11/52
IGY Immune Technologies & Life Sciences Inc.
BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS
June 24, 2009
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
12/52
IGY Immune Technologies & Life Sciences Inc.
BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS
August 3, 2009
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
13/52
IGY Immune Technologies & Life Sciences Inc.
BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS
I suffer no illusions that this will be an
easy process. It will be hard. But I also
know that nearly a century after Teddy
Roosevelt first called for reform, the cost of
our health care has weighed down our
economy and the conscience of our nation
long enough. So let there be no doubt;health care reform cannot wait, it must
not wait, and it will not wait another year.
- President Barack Obama, February 2009.
Under the proposed Preservation of Antibiotics for Medical Treatment Act, or PAMTA, newly-developedantibiotics couldnt be given to farm animals unless they were sick. The casual use of already-establisheddrugs would be restricted.
- Brandon Keim, Wired Magazine, July 21, 2009
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
14/52
IGY Immune Technologies & Life Sciences Inc.
BUILDING THE IMMUNE SYSTEM AND TREATING WORLD HEALTH PROBLEMS
Focusing in the immune system isa natural evolution in fight againstdiseases. Medical science isrecognizing the importance of
strengthening innate immunesystem and reducing reliance onantibiotics.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
15/52
IGY Immune Technologies & Life Sciences Inc.
THE TECHNOLOGY
Breakthrough
IRIs ground-breaking technology opens
the wide doorway to a whole new
science.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
16/52
IGY Immune Technologies & Life Sciences Inc.
Viral infections include:
All colds and flu
Most coughs Most sore throats, and
Usually involve several
parts of the body
THE TECHNOLOGY
IgY Works on Both Viral and Bacteria Infections
Bacterial infections include:
Strep throat
Urinary tract infections Most ear infections
Some sinus infections, and
Are usually localized at a
single point in the body
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
17/52
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
18/52
IGY Immune Technologies & Life Sciences Inc.
ANTIBODY YIELD FROM HENS
THE TECHNOLOGY
A laying hen can produce approximately 300 eggs annually and the volume
of one egg yolk is approximately 15 ml.
This could supply close to 100g of antibody per hen per year.
Each Eggs contain approximately 3-5mg IgY per ml of yolk (70-100mg of
total IgY antibody depending upon the size of the egg)
Of this total and depending on the concentration level required for
commercial effectiveness, our technology can generate as little as10% or as
much as 75% antibody against a specific antigen.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
19/52
IGY Immune Technologies & Life Sciences Inc.
ADVANTAGES OF ANTIBODIES FROM EGG YOLKS OVER MAMMALIAN ANTIBODIES
THE TECHNOLOGY
a. A single egg contains as much antibody as an average bleed from a rabbit. In addition,
egg collection is simple and noninvasive. Eggs are generally laid on a daily basis,
whereas a rabbit may only be bled once every 2-3 weeks.
b. Chickens require only a one month immunization regimen to obtain high titers of
polyclonal antibody. To ensure a rabbit is producing high titers of antibody, the
immunization procedure requires up to 2-3 months.
c. Similar amounts of antigen are required to immunize chickens and rabbits, but daily egg
collection occurs over a month and titers generally remain high during this period. A
rabbit may be bled only once every 2-3 weeks and the amount of antibody contained in
the sera is equivalent to the amount of antibody in a single egg.
d. Because the phylogenetic distance between birds and mammals is great, chickens are
very useful for producing antibodies against conserved mammalian proteins. Typically, 1-
5% of rabbit sera will be comprised of antibodies against a specific mammalian antigen.
About 2-10% of a chicken egg yolk is comprised of antigen-specific antibodies. In
addition, very highly conserved mammalian proteins sometimes fail to elicit an immune
response in rabbits but antibodies against these proteins are often successfully produced
in the avian system.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
20/52
IGY Immune Technologies & Life Sciences Inc.
THE PROCESS OF MAKING IGY ON A COMMERCIAL SCALE
160,000
eggs per
day.
ONE
KILO of
50%
Pure IgY
350
birds =10,500
eggs
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
21/52
IGY Immune Technologies & Life Sciences Inc.
THE PROCESS OF MAKING IGY ON A COMMERCIAL SCALE
Eggs arebroken at aCFIA eggstation
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
22/52
IGY Immune Technologies & Life Sciences Inc.
THE PROCESS OF MAKING IGY ON A COMMERCIAL SCALE
then mixed
with water andcentrifuged tocreate a Water
SolubleFraction,containing thedesired IgY.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
23/52
IGY Immune Technologies & Life Sciences Inc.
THE PROCESS OF MAKING IGY ON A COMMERCIAL SCALE
The prototypefacility was over$10 million indesign andinstallation.Capable ofproducing up to2,000 kg permonth of IgY.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
24/52
IGY Immune Technologies & Life Sciences Inc.
ISOLATION OF IGY FROM EGG YOLKResults: SDS-PAGE
IgY
Rm rt+w1 w2 el
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
25/52
IGY Immune Technologies & Life Sciences Inc.
App. 60 % purity
IgYResults: Size exclusion chromatography
ISOLATION OF IGY FROM EGG YOLK
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
26/52
IGY Immune Technologies & Life Sciences Inc.
EFFECTIVENESS OF IGY FOR SALMONELLA
THE TECHNOLOGY
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
27/52
IGY Immune Technologies & Life Sciences Inc.
COMPETITIVE ADVANTAGES
THE TECHNOLOGY
Higher concentration of IgY (traditional 5% purity vs. 25% or >)
Fats are removed
No Cholesterol
Pharmaceutical grade
Tasteless and odorless
Can be designed for a variety of applications
Can be used in an aerosol
No competitive technology
Comprehensive patents on intellectual property
.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
28/52
IGY Immune Technologies & Life Sciences Inc.
INTELLECTUAL PROPERTY PROTECTION
THE TECHNOLOGY
Our Companys value lies in our ability
to continuously generate new IP
protection for IgY. We are regularly
adding new patents to our existing
portfolio.
Patent approvals are sought
internationally for ingredients and
processes and for products that are
developed.
We have chosen not patent certain key
elements of our process for addedprotection.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
29/52
IGY Immune Technologies & Life Sciences Inc.
MANUFACTURING & PRODUCTION
THE TECHNOLOGY
Control over egg supply chain
Eggs are the most economical and practical solution as chickens lay eggs
regularly, so there is a continual source of antibody Agreements secured with suppliers
economical and practical solution deal to the leftover egg byproduct
.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
30/52
IGY Immune Technologies & Life Sciences Inc.
MARKET SEGMENTS
COMMERCIAL APPLICATIONSOur commercial applications fall across 4 primary sectors which means we can grow
our product base and revenue streams against any cyclical variations.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
31/52
IGY Immune Technologies & Life Sciences Inc.
MARKET SEGMENTS: MEDICINES
IGY SPECIFIC - CLOSTRIDIUM DIFFICILE (C.DIFFICLE)
Ig(Y) specific for Clostridium Difficile Bacteria.
Under development with Dr. Michelle Alfa, University of
Manitoba and St. Boniface Hospital
Expected combined phase I and II trials to be completed
within 24 months, and a marketable pharmaceutical ready
for 2012
Expected to generate over a Billion dollars of revenue in
North America alone.
Dr. Alfa has already proven the viability of generating theantigens from the eggs, the problem remained commercial
ability to produce an Ig(Y) Specific, which has now been
solved.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
32/52
IGY Immune Technologies & Life Sciences Inc.
Potentially lethal cases ofC. Difficile rocketed from 1990s to 2004
Cases had increased from 1,000 in 1990 to over 35,000 in 2003
44,488 cases ofC. Difficile in > 65 year olds in 2004.
Good new stats here on C. Dif. with 7,000 cases per day, and 300
mortalities per day.
$51.5 million in health care costs, per day in the United States. That is
$18.8 Billion per year in costs. This just for C. Diff. not to mention MSRA.
A single occurrence of CDI adds about $3,700 to a hospital bill and can
mean three or more additional nights in the hospital.
BBC News. http://news.bbc.co.uk/2/hi/health/4186834.stm
LETHAL HOSPITAL BUG CASES ROCKET, UNITED KINGDOM
MARKET SEGMENTS: MEDICINES
CLOSTRIDIUM DIFFICILE (C.DIFFICLE)
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
33/52
IGY Immune Technologies & Life Sciences Inc.
MARKET SEGMENTS: FUNCTIONAL FOODS
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
34/52
IGY Immune Technologies & Life Sciences Inc.
MARKET SEGMENTS: FUNCTIONAL FOODS
Multi-Million dollar letter of intent signed December 25th,
2008.
Pharma Foods markets a variety of Ig(Y) products.
Majority of Asians and Mexicans suffer from HP bacteria.
Second part of agreement to produce H5N1 (avian flu)
antibody.
Current processes provide approximately 5% purity of H. Pylori
IGY. Our process provides 50-75% purity of H. Pylori IGY.
PHARMA FOODS INTERNATIONAL CO., LTD
Discussions with Pharma Company in China to produce a H.Pylori
pharmaceutical.
http://images.google.ca/imgres?imgurl=http://web.1.c2.audiovideoweb.com/1c2web3536/IgYYogurtinJAPAN%20-%20Credit%20-%20Pharma%20Food%20International%20Co.,%20Ltd..jpg&imgrefurl=http://portal.acs.org/portal/PublicWebSite/pressroom/newsreleases/WPCP_012358&usg=__k9y4wb1uZIurOwmxeSrKkvD728c=&h=2448&w=3264&sz=1769&hl=en&start=2&sig2=lbF3YDuwfTmWAogDhdOKLA&tbnid=fiucbdmfI-4ZNM:&tbnh=113&tbnw=150&prev=/images?q=gut+yogurt+korea&hl=en&rlz=1T4ADBF_enCA317CA318&ei=nMtnSs_iLozflAfRgrDECQ -
8/14/2019 Igy_presentation Jan 2010 NML WPG
35/52
IGY Immune Technologies & Life Sciences Inc.
MARKET SEGMENTS: FUNCTIONAL FOODS
http://www.pharmafoods.co.jp
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
36/52
IGY Immune Technologies & Life Sciences Inc.
MARKET SEGMENTS: AGRIBUSINESS AND PACKAGED CONSUMER MEATS
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
37/52
IGY Immune Technologies & Life Sciences Inc.
MARKET SEGMENTS: COSMECEUTICALS
The cosmeceuticals market is forecasted to reach $21 billon by 2012
Sales of natural body care products are thriving with 14% growth in 2007
and annual compound growth of 57% since 2004
Skin care, hair care and colour cosmetic cosmeceuticals showed an overall25% gain in the retail sector between 2003 and 2007
THE COSMECEUTICALS MARKET
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
38/52
IGY Immune Technologies & Life Sciences Inc.
MARKET SEGMENTS: COSMECEUTICALS
Our Acne Product is an antibody tailored skin treatment. The antibody is made in a similar way to
that of making a vaccine. The antibody is a specific immunoglobulin (IgY) that we produce targets
for Propionibacterium Acnes or P. Acnes for short. The exact cause for all forms of acne (pimples,
whiteheads, blackheads, mild and severe lesions) is not known but researchers believe there are
many related factors. However, common to all forms of acne is the culprit, P. Acnes. Our acnetreatment inactivates P. Acnes and thereby removes the major cause of skin inflammation and
disease. Without P. Acnes the skin will heal and new lesions will not occur.
BeforeTreatment
AfterTreatment
A natural and a safe alternate to AntibioticTreatment for Acne
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
39/52
IGY Immune Technologies & Life Sciences Inc.
MARKET SEGMENTS: COSMECEUTICALS
1. Cleansing Mousse : Contains Natural Oceanic Clay, Herbs and Vitamin E to protect and
maintain the skins health while natural emulsifiers and scrubbing beads remove makeup
and soils effectively.
2. Natural Oceanic Clay mask with IgY: Anti-Acne Clay Mask with IgY helps combat
blemishes and blackheads in a double action through the combined forces of our Natural
Oceanic Clay and APA - IgY.
3. Moisturizing Cream with IgY: This anti-acne moisturizing cream is formulated as a
treatment for prevention of acne skin infections caused by Propionibacterium acne. Our
unique antibody treatment APA-IgY (Anti Propionibacterium Acnes-IgY) penetrates theskin and destroys the Propionibacterium Acne-bacteria that is common among all forms of
acne, and prevents the appearing of blackheads and blemishes. Panthenol and Sunflower
Oil moisturizes the skin. This beneficial formula completes the treatment of acne while
maintaining the healthy condition of the skin.
The IGY Skincare Program is a completesystem of three products
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
40/52
IGY Immune Technologies & Life Sciences Inc.
MARKET SEGMENTS: COSMECEUTICALS
"Proactiv has become a phenomenon by transformingthe way consumers think about pimples. The brand
captured public attention by hiring stars for its
infomercials like Vanessa Williams, Jessica Simpson
and Sean Combs to lay bare their valiant struggles to
attain flawless skin, effectively turning acne into a
celebrity malady. But the companys real innovation
was repositioning mild breakouts from a routine
annoyance that a dab of Clearasil might fix to a
preventable condition, like cavities, requiring vigilant
daily upkeep.
The brand now has more thanfive million active
customers and annual worldwide sales of about $850
million, 70 percent of which are in the United States.
Right now, we own acne, said Greg Renker, a chief
executive of Guthy-Renker, the direct-response
television company that sells Proactiv
New York Times, October 2007
INFOMERCIAL STRATEGY
http://flaggedforfollowup.typepad.com/.shared/image.html?/photos/uncategorized/2007/10/18/proactive_jessica_simpson.jpg -
8/14/2019 Igy_presentation Jan 2010 NML WPG
41/52
IGY Immune Technologies & Life Sciences Inc.
STRATEGIC TIMELINE
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
42/52
IGY Immune Technologies & Life Sciences Inc.
GloBayne Marketing
International
FedNor
Maple Leaf Foods Provincial Health Care
Ministries
National Research
Counsel, IRAP program Ironwood Clay Company
LEVERAGE RESOURCES THROUGH PARTNERSHIPS
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
43/52
IGY Immune Technologies & Life Sciences Inc.
THE OPPORTUNITY LIES IN OUR LEADERSHIP
While the current budget is set for cosmeceutical and
nutraceutical applications, the opportunity for the National
Microbiology Lab lies in a joint effort to create the first
pharmaceutical IgY product.
A C. Difficile IgY Specific remains our top priority. Much of the phase I & II clinical work has been completed
by the SBRC.
Steps to move forward include acquiring a government
approved vaccine for C. Difficile, producing a test sample of
IgY Specific C. Difficile, completing the requirements forhuman testing.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
44/52
IGY Immune Technologies & Life Sciences Inc.
ELISAC.difficile
00.10.20.30.40.50.60.70.8
62.5 125 250 500 1000 2000 4000 8000[IgY] (ng/mL)
A(4
05
nm
)SigmaIRI 27067IRI 07067IRI 27067 Eggcellent Extractblank (diluent)3% gelatin coated vs 27067 extract3% gelatin coated vs 27067
THE OPPORTUNITY LIES IN OUR LEADERSHIP
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
45/52
IGY Immune Technologies & Life Sciences Inc.
IGY C. DIFFICILE SPECIFIC SAVE LIVES & MONEY
Currently, 300 people per day die as a result of C. Difficile
related causes in the USA everyday.
The cost to the US health-care system is $51.5 million per
day.
The average cost of a stay in a Canadian hospital is $1,350,
escalating to $2,500 per day in an isolation room.
We estimate that at 75% of the patient load in a health
care facility taking C. difficile IgY Specific antibodies, at
$3.50 per day would save roughly $16 billion in health carecosts in North America and 120,000 lives annually.
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
46/52
IGY Immune Technologies & Life Sciences Inc.
IMAGINE THE POSSIBILITIES
Candida albicans
Rotavirus
Streptococcus mutans
Listeria monocytogenes Parvovirus
Celiac and colitis
Cystic fibrosis
Staphylococcal enterotoxin BAs a tool in proteomics
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
47/52
IGY Immune Technologies & Life Sciences Inc.
Terry N. Dyck President, CEO
Sharad Mistry Chief Financial Officer
John Mason Chief of Research
David Mason Chief of Operations
MANAGEMENT TEAM
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
48/52
IGY Immune Technologies & Life Sciences Inc.
Dr. Stu Richie Canadian Poultry Consultants Ltd.
Roger Upton, President Ironwood Clay Company
Ian Cooke Facilities Engineer
Ameann DeJohn Ameann Solutions, CA
Bob Jones, Principle Scientia Advisors
John Henderson, President Brain Box Communications
CONSULTANTS
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
49/52
IGY Immune Technologies & Life Sciences Inc.
Ron Bayne President of GloBayne
Dr. John Webb Director of Science, Maple Leaf Foods
Ken Boshcoff Governmental Affairs
Dr. Frank Mauro Periodontist
Dr. Sheetal Sapra Dermatology
Dr. Keith Ly Dermatology
Dr. Jeanette Jacknin Dermatology
ADVISORY BOARD
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
50/52
IGY Immune Technologies & Life Sciences Inc.
LEGAL TEAM
Michael Strickland, corporate affairs Bust & Partners, Thunder Bay, ON
Jay Lefton, securities law Ogilvy Renault, Toronto
Stephen Burri, Intellectual Property Miller Thomson, Vancouver
John Cameron, BDO Dunwoody Auditors, Thunder Bay
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
51/52
IGY Immune Technologies & Life Sciences Inc.
Terry N. Dyck, President and CEO
Kevin Nephin
Dr. Brian Scott
Rashid Ahmed
Sharad Mistry
BOARD OF DIRECTORS
-
8/14/2019 Igy_presentation Jan 2010 NML WPG
52/52
A New Beginning
Boosting the Immune System,
Prevention is the Cure.
QUESTIONS AND ANSWERS